Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Waldenstrom's macroglobulinemia confirmed by IgM gammopathy and bone marrow biopsy~  * Presence of lymphoplasmacytic cells~ * CD20+ plasma cell dyscrasia on the majority of malignant cells~ * Bone marrow involvement of 20-50% by core needle biopsy of at least 1.5 cm in length~* Clinical indication for initiation of treatment, including 1 or more of the following characteristics:~  * Symptoms associated with the disease (e.g., fatigue, asthenia, or painful adenopathy)~ * Anemia~ * IgM greater than 3 g/L~ * Progression as indicated by a rate of IgM rise of more than 0.5 g over 6 months~* No myelodysplastic syndromes or profound hypocellularity of the bone marrow~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* WHO 0-2~Life expectancy~* More than 3 months~Hematopoietic~* Absolute neutrophil count greater than 1,500/mm\^3~* Total B-lymphocyte count less than 5,000/mm\^3~* Platelet count greater than 100,000/mm\^3~* No hyperviscosity syndrome~Hepatic~* Bilirubin no greater than 1.5 mg/dL~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 year after study completion~* No uncontrolled CNS disease~* No serious nonmalignant disease that would preclude study participation~* No other concurrent active malignancy except controlled skin cancer or prostate cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)~* More than 4 months since prior rituximab~* No prior radioimmunotherapy~Chemotherapy~* No prior high-dose chemotherapy (unless patient has had prior back-up stem cell collections)~* More than 6 weeks since prior chemotherapy~Endocrine therapy~* More than 4 weeks since prior corticosteroids~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).